baber/WOPTO huggingface dataset:
Patent EP-0686673-A1 (EP)
Inventor: ALFTER FRANK DR
IPC: C08K5/3417
Filed: 1995-06-02
Abstract: Novel isoindoline pigments of formula (I) are claimed, as are also (i) prepn. of (I) by reacting an isoindoline of formula (II) having nucleophilically-exchangeable gps. X and Y in the 1- and 3-positions with a cpd. of formula (III) in which the H atoms of the -CH2- gp. are CH acids so as to give an intermediate of formula (IV) which is then reacted with a benzimidazolone of formula (V); and (ii) the use of (I) in pigmenting high mol. wt. organic materials. R<1> = CN; R<2> = (a) CN; (b) an (un)satd. (non)aromatic 5-7 membered N, O and/or S heterocyclic ring opt. modified by condensation or bridging to further heterocyclic or isocyclic ring systems; (c) -CONR<6>R<7> where R<6> and R<7> = H or 1-4C alkyl; or (d) -CONR<6>R<8> where R<8> = unsubstd. or with at least 5 1-4C alkyl, halogen, CF3, 1-4C alkoxy, carbo(m)ethoxy or carbonamide- or with one 1-4C alkyl or phenyl gp.-substd. carbonamide, NO2, 1-4C alkylamino or OH-substd. (un)satd., (non)aromatic, iso- or hetero-cyclic (N, O and/or S) 5-7-membered ring opt. modified as per the ring of (b) above; or R<1> and R<2> together = ring as per (b) above opt. substd. as per (d) but excluding NO2; R<3> = H, 1-4C alkyl, phenyl, 1-4C alkoxy, halogen or 1-4C acylamino; R<4> = H, 1-4C alkyl, halogen, CF3, MeO, EtO or NO2; m = 1, 2, 3 or 4; n = 1, 2 or 3; and R<5> = H or 1-4C alkyl.
Patent EP-0687595-A1 (EP)
Inventor: BOLLAERT MATTHEW C
IPC: B60R21/231
Filed: 1995-06-13
Abstract: An air bag for use with an inflation fluid source includes a body portion (170) defining an inflation fluid volume (172) into which inflation fluid is directed to inflate the body portion. A mouth portion (160) of the air bag (10) is connected with the body portion (170). The mouth portion (160) defines an inflation fluid opening (177) in fluid communication with the inflation fluid volume (172). The inflation fluid opening (177) is defined in part by opposite fabric material panels (40,42). Each panel (40,42) comprises at least two layers (130,132,140,142) of fabric material in abutting engagement with each other. At least two layers (130,132,140,142) of fabric material encircle a retaining ring (174) for attaching the air bag mouth portion (160) to the inflation fluid source.
Patent EP-0690149-A1 (EP)
Inventor: UCHIYAMA NAOKI C O SANDA KOJYO
IPC: C25D3/56
Filed: 1995-06-30
Abstract: An electroplating solution (A), comprises an aqueous solution consisting essentially of lead phenolsulfonate: 1 to 250 g/liter in terms of Pb content; tin phenolsulfonate: 0.1 to 250 g/liter in terms of Sn content; phenolsulfonic acid: 20 to 300 g/liter; polyoxyethylene polyoxypropylene alkylamine: 1 to 50 g/liter; a 1-naphthaldehyde derivative: 0.001 to 1 g/liter; and an aldol sulfanilic acid derivative: 0.1 to 30 g/liter; or an aqueous solution (B) consisting essentially of lead methanesulfonate: 1 to 250 g/liter in terms of Pb content; tin methanesulfonate: 0.1 to 250 g/liter in terms of Sn content; methanesulfonic acid: 20 to 300 g/liter; polyoxyethylene polyoxypropylene alkylamine: 1 to 50 g/liter; and an aldol sulfanilic acid derivative: 0.1 to 30 g/liter. Each of the electroplating aqueous solutions (A) and (B) contains 50 ppb or less radioactive isotopes, whereby Pb-Sn alloy bump electrodes with improved uniformity in height and improved surface smoothness can be formed on a surface of a semiconductor wafer.
Patent EP-0695974-A1 (EP)
Inventor: SHIBAI YASUHIRO
IPC: C09C3/10
Filed: 1995-07-17
Abstract: A liquid developer comprises a nonaqueous dispersion medium and coloring resin particles, containing a pigment and/or a dye, dispersed in the nonaqueous dispersion medium and microcapsularized by resin which is insoluble in the dispersion medium.
Patent EP-0698700-A1 (EP)
Inventor: HELLWIG FRANK
IPC: E04B5/02
Filed: 1995-08-23
Abstract: The structure forms each storey-layer from individual base elements (20), which are supported and fastened between two rows of vertical pillars. The elements have continuous concrete, or steel-reinforced concrete, panels (21), whose length corresponds to the internal width between both rows of pillars. The panels cover beam arrangements, consisting of two U-shaped channels (22), which each have one flange (23) bonded to the panel by shaped elements (24). The web (25) between the flanges of each channel runs vertically, and is arranged flush with a side edge of the panel. The endwall of each panel has an integrated tensioning member (34), and the adjacent channels of neighbouring base elements are bolted to one another.
Patent EP-0693490-A1 (EP)
Inventor: KANNO HISASHI
IPC: C07D409/12
Filed: 1995-07-18
Abstract: A 2-phenoxy-6-thienylmethyloxypyridine derivative of formula (I) :
       
    wherein: 
   R represents hydrogen, a halogen, cyano, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ haloalkyl, C₁-C₄ alkylamino, or di(C₁-C₄ alkyl)amino; 
   each X, which may be identical or different if n is greater than 1, represents a halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkylthio, or C₁-C₄ haloalkyl; 
   each Y, which may be identical or different if m is greater than 1, represents a halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, or C₁-C₄ haloalkylthio; 
   m represents an integer of 0 to 5; and 
   n represents an integer of 0 to 3.
Patent EP-0694291-A1 (EP)
Inventor: HASSLER WILLIAM L
IPC: A61B18/12
Filed: 1995-07-27
Abstract: Tissue impedance or tissue impedance in combination with tissue temperature is used to control electrosurgical tissue treatment. Tissue impedance alone provides better control of electrosurgical treatment by determining an initial maximum tissue impedance, a minimum tissue impedance selecting a point between the maximum and minimum impedances, preferably the average, as an impedance threshold, and turning off rf power to the electrosurgical instrument when the impedance reaches the threshold as it rises from the minimum. Control may also be by the combination of tissue impedance and temperature. Temperature is controlled to maintain a selected preferred temperature and a maximum temperature is also selected so that if the tissue reaches the maximum temperature, power is turned off. Impedance control is combined with temperature control so that the temperature of the instrument is maintained at a selected preferred temperature unless a maximum temperature is exceeded, which normally will not happen. The impedance is also monitored with maximum and minimum values being determined as well as a threshold impedance between the max and the min. When the threshold, preferably the average impedance, is reached, power is removed from the instrument.
Patent EP-0703389-A1 (EP)
Inventor: DEQUENNE MICHEL
IPC: F16H3/12
Filed: 1995-09-21
Abstract: The process involves driving the front wheels (4) by the vehicle engine (1) via the mechanical gearbox (2) when a friction clutch (3) is engaged by operation of a hydraulic cylinder (9) controlled by a valve (12) in response to the clutch pedal (15) of displacement of the clutch lever (10). The force exerted on the manual gear lever (19) is signalled by a strain gauge (21). When this signal exceeds a predetermined threshold the starter motor (16) is activated for a few milliseconds, applying torque to a flywheel (7) so that the gear lever can be moved towards the home position.
Patent EP-0729540-A1 (EP)
Title: Door or window hinge plate
Inventor: POLITI SANDRO
IPC: E05D7/00
Filed: 1994-11-10
Abstract: In the proposed door or window hinge plate, the spigot component (1) on which the sleeve (2) is placed is provided with a spigot (5) which is mounted in such a way that its height can be altered. An adjustable element (7) in the form of a cap screw (19) engages in a thread (17) cut inside the spigot (5). Axial movement of the adjustable element (7) is prevented by an elevation (15) which protrudes radially into the bore (14). In addition, elevations (15) engage in a groove (11) in the spigot (5), allowing the spigot (5) to move axially but not to rotate. A tool can be inserted through an aperture (22) at the lower end of the spigot section (1). This tool can engage in an inner recess (21) in the adjustable element (7), thereby facilitating adjustment of the height of the spigot (5).
Patent EP-0733126-A1 (EP)
Inventor: WAGNER ROBERT E JR
IPC: C12Q1/6858
Filed: 1994-11-04
Abstract: L'invention concerne un procédé de détection de mutations, comme le changement d'une seule base ou l'addition ou la suppression d'environ une à quatre paires de bases, qui se fonde sur l'utilisation d'une protéine immobilisée fixatrice de mésappariements de bases d'ADN, comme des agents mutagènes, qui fixe un hybride d'acide nucléique ayant un mésappariement d'une seule base ou une base ou des bases non appariées, ce qui permet de détecter des mutations n'impliquant que le changement d'une seule base dans une séquence nucléotidique. Ce type de procédé s'utilise pour diagnostiquer une pluralité d'états pathologiques ou de prédispositions à des maladies, qui sont majeurs, pour détecter la présence d'un oncogène ayant subi une mutation et pour isoler ou extraire, par chromatographie par affinité, des molécules d'ADN duplex contenant des mésappariements, tels que des molécules contenant des erreurs dans des échantillons d'ADN amplifié par PCR. L'invention concerne également des trousses utilisées pour mettre lesdits procédés en oeuvre.
Patent EP-0729324-A1 (EP)
Inventor: WONG VERNON G
IPC: A61F2/14
Filed: 1994-11-09
Abstract: Implants comprising active agents are employed for introduction into a suprachoroidal space or an avascular region of an eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.
Patent EP-0737229-A1 (EP)
Inventor: FISHER DENNIS H
IPC: C08L67/06
Filed: 1994-11-14
Abstract: This invention is the polycapped oligomer adduct of a long chain fatty acid with a multi hydroxy functional or multi epoxy functional compound. This polycapped oligomer is useful in resin compositions to enhance the performance of thermoplastic low profile additives which improve the surface quality of molded composites such as automotive body panels.
Patent EP-0735825-A1 (EP)
Inventor: SALUS MILOS
IPC: A23C19/05
Filed: 1994-12-14
Abstract: A synergy effect of the combination of a disaggregation of milk fat, casein micelle complexes and a partial disaggregation of soluble protein micelle complexes taking place in the homogeniser at a temperature of 55 - 74  DEG C under the pressure of 4-8 MPa, while gradually adding of defined amount of soluble calcium salt, at least in two doses, to the milk before curdling in various steps of the treatment with the aim to optimise the free-bound calcium ratio bringing about a positive effect on the yielding of proteins at curdling is the principal behind the proposed method of milk pre-treatment in the enzymatic cheese and quarg production.
Patent EP-0749324-A1 (EP)
Inventor: HENNESSY DESMOND RONALD
IPC: A61K47/44
Filed: 1995-03-10
Abstract: A wool grease fraction having a substantially neutral oxidation profile and a formulation for topical application to wool producing animals, said formulation comprising a light stable active agent in a vehicle comprising a wool grease fraction having a substantially neutral profile. A formulation for topical application to wool producing animals, said formulation comprising a light stable active agent in a vehicle comprising at least one of a sterol ester, a wax ester, a triterpene ester containing substantially unoxidised isocholesterols or an analogue thereof. Processes for manufacturing the fractions and formulations and methods of controlling pests employing the formulations.
Patent EP-0749580-A1 (EP)
Inventor: FODSTAD OYSTEIN
IPC: G01N33/574
Filed: 1995-03-10
Abstract: The invention relates to a method and apparatus for detecting specific target cells in a simple and time-saving way, using paramagnetic particles, antibodies recognizing the Fc portions of target-cell associating antibodies and target-cell associating antibodies directed to specific antigen determinants in the target-cell membranes. Incubation of the cell suspension with detergent and/or second antibodies or antibody fragments, prelabeled or not with fluorescent agents, metallocolloids, radioisotopes, biotin complexes or certain enzymes allowing visualization, dramatically increase the specificity of the method. The method and apparatus described provides a solid support and permanent record which is easily viewed by microscopy, permits viewing and quantification of the whole specimen rather than small fractions thereof and allows the use of large specimen volumes to be analysed, the device may also be scanned automatically by conventional densitometric technology. The method and apparatus can be used for isolation of the target cells by magnetic field application, and a kit and apparatus for performing the method according to the invention is described.
Patent EP-0758314-A1 (EP)
Inventor: DAVISON BRUCE EVERETT
IPC: C07C69/60
Filed: 1995-05-09
Abstract: The present invention relates to compounds which are useful as sunscreens. The compounds persist on the skin for much longer than conventional sunscreens because they comprise a Michael acceptor linked directly or indirectly to a chromophore. The Michael acceptor is capable of undergoing a conjugate addition reaction with thiol groups present in cysteine residues of keratin and thus the compound is chemically bound to the skin and will not be removed by immersion in water.
Patent EP-0751794-A1 (EP)
Inventor: LAWLESS MICHAEL W
IPC: A61M5/142
Filed: 1995-05-10
Abstract: A disposable pumping cassette having an integral auxiliary flow control and pressure monitoring member is used for delivering a medicinal fluid to a patient. The pumping cassette includes an elastomeric member mounted in a rigid body having an inlet and an outlet. An inlet valve and an outlet valve on the cassette are opened, and the flow control is positioned to allow the medicinal fluid to flow freely through the cassette, priming it before the outlet is connected to the patient. The cassette is then coupled to an associated pump driver, closing the flow control to disable free fluid flow through the cassette, and the outlet of the cassette is coupled in fluid communication with the patient's body. The medicinal fluid is drawn into a pumping chamber formed in the rigid body as a plunger of the associated pump driver is drawn up from the elastomeric membrane at a recess formed in the rigid body. The plunger is then advanced downwardly, forcing the elastomeric membrane into the pumping chamber to deliver the medicinal fluid to the patient. The pressure of the fluid delivered to the patient is monitored through contact of the auxiliary flow control member with the elastomeric membrane over an outlet channel of the cassette.
Patent EP-0826143-A1 (EP)
Title: Procede pour determiner la teneur d'oxygene dissous dans l'eau
Inventor: ELSON JESSE
IPC: G01N21/78
Filed: 1995-05-15
Abstract: L'invention concerne un procédé pour déterminer la concentration d'oxygène dissous dans un échantillon d'eau liquide, selon les étapes suivantes: a) sélection d'un échantillon d'eau liquide dont le volume est connu et dont la teneur en oxygène reste à déterminer; b) apport d'additif à l'échantillon pour former un mélange; ces additifs comprennent un sel métallique oxydable constitué d'un cation métallique et d'un anion inorganique ou organique qui, avec le cation, forme un sel métallique oxydable hydrosoluble, au moins un composé métallique alcalin hydrosoluble sous forme d'oxyde métallique alcalin, ou bien un hydroxyde de métal alcalin ou un sel de métal alcalin et un acide faible; et au moins un indicateur d'oxydation-réduction pouvant changer de couleur au moment de l'oxydation du sel métallique oxydable suite au contact avec l'oxygène dissous dans l'échantillon liquide, la nouvelle couleur indiquant la concentration de l'oxygène dissous dans l'échantillon liquide; c) élimination de tout contact sensible entre le mélange et l'oxygène de l'atmosphère; et d) évaluation de la concentration d'oxygène dissous dans l'échantillon liquide par comparaison entre la couleur du mélange et une couleur prédéterminée indiquant la concentration d'oxygène dissous dans l'échantillon d'eau.
Patent EP-0765500-A1 (EP)
Inventor: JAFFA BRENT ERNEST
IPC: G06F13/36
Filed: 1995-06-13
Abstract: Ce circuit en pont (10) comprend un microprocesseur (20) ayant un premier port E/S, qui est couplé à un bus SCSI (11), et un second port E/S qui est couplé par des émetteurs/récepteurs (21) à un bus EISA (12). Ce circuit en pont comprend également un contrôleur d'interface EISA (22), ayant des lignes de commande (32) couplées au bus EISA et aux émetteurs/récepteurs, qui permettent au microprocesseur de demander et d'utiliser le bus EISA en mode temps partagé. Afin d'obtenir une vitesse d'exploitation élevée, ce circuit en pont comprend en outre un module de mémoire (23), qui est couplé par l'intermédiaire d'un bus privé (24) au second port E/S du microprocesseur (20) et qui envoie des instructions le long du bus privé directement au mircoprocesseur, sans produire de signaux sur le bus EISA. Par ailleurs, afin d'empêcher les interblocages sur le bus privé, ce circuit en pont comprend un circuit anti-interblocage (25) qui est couplé au microprocesseur (20) et au bus privé (24) et au contrôleur d'interface EISA (22). Ce circuit anti-interblocage détecte l'apparition d'un événement prédéterminé (figures 5, 6, 7) pendant une série de transmissions de données entre le microprocessuer et le bus EISA. Lorsque cette détection se produit, le circuit anti-interblocage guide le microprocesseur pour que celui-ci arrête la série des transmissions de données le long du bus EISA et du bus privé avant la fin de la série; et il guide le microprocesseur pour que celui-ci ne redémarre pas la série sur le bus privé aussi longtemps que le bus EISA n'est pas requis. Pendant ce temps, les recherches d'instructions sur le bus privé peuvent se produire.
Patent EP-0765388-A1 (EP)
Inventor: WILSON KEITH P
IPC: C12N15/09
Filed: 1995-06-16
Abstract: Interleukin-1β converting enzyme ('ICE') processes an inactive precursor to the pro-inflammatory cytokine, interleukin-1β. The high-resolution structure of human ICE crystallized in complex with an inhibitor is determined by X-ray diffraction. The active site spans both the 10 and 20 kilodalton subunits. The accessory binding site is composed of residues from the p10 and p20 subunits that are adjacent to the two-fold axis of the crystal. The structure coordinates of the enzyme may be used to design novel classes of ICE inhibitors.
Patent EP-0765270-A1 (EP)
Inventor: AMBLI NILS O
IPC: B63H11/11
Filed: 1995-06-16
Abstract: La présente invention concerne un propulseur hydrojet destiné à un bateau. Le dispositif se compose d'une pompe de propulsion carénée (1). Un appareil gouvernant disposé à la sortie de la tuyère d'hydrojet (2) sert à commander la direction du bateau, le cassage d'erre ou le culage. L'appareil gouvernant comporte une structure à support et palier dans l'alignement de la bouche de tuyère (2), pivotant autour d'un axe vertical. Cet appareil gouvernant comporte par conception deux panneaux latéraux parallèles (10, 11) entre lesquels une tuyère directionnelle (16) pivote autour d'un axe horizontal (14, 15). Une coquille d'inversion de flux (21) montée sur pivot est disposée, entre les deux panneaux latéraux (10, 11), en dessous de la tuyère directionnelle (16) dont la section est rectangulaire. Cette coquille d'inversion de flux (21) est en relation mécanique (22-24) avec la tuyère directionnelle (16) de sorte que lors du relèvement de l'extrémité avant de la tuyère directionnelle (16), la coquille d'inversion de flux passe d'un positionnement en dessous de la tuyère directionnelle (16) à une position d'ouverture vers le bas.
Patent EP-0769935-A1 (EP)
Inventor: REINER ALBERTO
IPC: A61K9/26
Filed: 1995-07-15
Abstract: On a préparé des comprimés à partir d'une base de gomme à macher à laquelle on a ajouté au moins un principe actif se présentant sous la forme de particules dont au moins certaines peuvent être micro-encapsulées ou enrobées afin d'assurer une libération retardée, et on a laqué les comprimés à l'aide d'une laque protectrice à base d'un dérivé de cellulose et/ou de polyéthylèneglycol dans un solvant aqueux ou alcoolique.
Patent EP-0772655-A1 (EP)
Title: Sirop acrylique durcissable en materiau reticule viscoelastomere
Inventor: BENNETT GREGGORY S
IPC: C09J7/02
Filed: 1995-07-28
Abstract: Des polymères dissous dans des solvants monomères constituent un sirop applicable sous forme de revêtement et pouvant être durci, afin d'obtenir un matériau viscoélastomère, quand des groupes de clivage α sensibles aux rayonnements, soit dans le polymère, soit dans l'un des monomères, sont exposés à un rayonnement ultraviolet. Les polymères dissous peuvent être préparés à partir des solvants monomères ou leur être ajoutés, afin d'obtenir le sirop.
Patent EP-0783784-A1 (EP)
Inventor: BURT MICHAEL GRAHAM
IPC: H01S5/32
Filed: 1995-09-29
Abstract: An optical fibre comprises a tubular glass cladding (1) with a central opening (2), filled with a colloidal solution of quantum dots (4) in a support medium (3). The quantum dots may be caused to produce luminescence in response to input optical radiation, for example to produce optical amplification or laser radiation. A waveguide with an active medium comprising colloidal quantum dots is claimed.
Patent EP-0790336-A1 (EP)
Inventor: TAMARU SHINJI
IPC: D04H1/544
Filed: 1995-10-02
Abstract: To provide a PTFE composite fiber having remarkably improved thermal bonding property, PTFE cotton-like materials which can be used for producing a non-woven fabric by thermal bonding method, processes for production thereof, a process for producing a split yarn, a process for producing a monofilament and a process for producing a multifilament having loop and/or branched structure. 
     A thermofusing resin layer is provided on the surface of the PTFE fiber. After lamination of the PTFE film and the thermofusing resin film, uniaxial stretching is carried out at a temperature between the melting points of the respective films.
Patent EP-0784674-A1 (EP)
Inventor: OXENBOLL KAREN M
IPC: C11D3/386
Filed: 1995-10-26
Abstract: PCT No. PCT/DK95/00425 Sec. 371 Date Apr. 4, 1997 Sec. 102(e) Date Apr. 4, 1997 PCT Filed Oct. 26, 1995 PCT Pub. No. WO96/13579 PCT Pub. Date May 9, 1996The present invention relates to novel lipolytic enzymes. More specifically the invention provides novel lipolytic enzymes having the properties of a lipase native to the strain Fusarium culmorum CBS 513.94, or has immunochemical properties identical or partially identical to those of a lipase native to the strain Fusarium culmorum CBS 513.94.
Patent EP-0794757-A1 (EP)
Inventor: ROZZI SHARON M
IPC: A61K6/083
Filed: 1995-11-28
Abstract: La présente invention concerne des revêtements pour des surfaces et tissus durs de la sphère buccale, lesquels revêtements réduisent l'adhérence des bactéries et substances protéiniques sur ces surfaces. L'invention concerne également des procédés de réduction de l'adhérence de ces substances sur de telles surfaces ainsi que des polymères à incorporer dans de tels revêtements.
Patent EP-0760669-A1 (EP)
Inventor: HRISTOV IVAN DIMITROV
IPC: A61K33/30
Filed: 1995-03-22
Abstract: The problem solved by the present invention is the creation of an antiasthmatic remedy breaking of the disease fits and leading to full healing. The substance of the decision lies in the combination of active components and their proportion: atropine sulphate 0,25 - 1,00 mg; papaverine hydrochloride 30,00-200,00 mg; caffeine purum 30,00-250,00 mg; ergotamine tartrate 0,25-2,00 mg; zinc sulphate 10,00-220,00 mg; sex hormones 0,25-1,00 mg, the sex hormones being diethylstilbestrol propionate or methandrostenol. The advantages of the composition are that it leads to stopping the asthmatic fits for 30-40 min, averts any new fits, and leads in practice to full healing.